GlassScriptPhysician profile
Feng Li
NPI 1568435394
$107,666.75
in general payments reported to CMS, 2019-2025
31 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $7,353 · 2021: $20K · 2022: $19K · 2023: $15K · 2024: $7,721 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $7,200 · Travel and Lodging: $4,773 · Food and Beverage: $3,562 · Education: $94.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,025.00 |
| Consulting Fee | $7,200.00 |
| Travel and Lodging | $4,772.95 |
| Food and Beverage | $3,562.15 |
| Education | $94.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $84,402.61 | 2019-2025 | |
| Micro-Tech Endoscopy USA, INC. | $10,148.02 | 2021-2025 | |
| Boston Scientific Corporation | $9,109.02 | 2019-2025 | Acquire, Exalt Model D, Spyglass Discover |
| Ovesco Endoscopy USA, INC. | $1,084.50 | 2024 | |
| Janssen Scientific Affairs, LLC | $506.41 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $307.93 | 2019-2025 | Entyvio, Eohilia |
| Medtronic, INC. | $299.20 | 2022-2025 | Gi Genius, Pillcam, Endoflip |
| Gilead Sciences, INC. | $265.85 | 2019-2023 | |
| Qol Medical, LLC | $189.05 | 2019-2024 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $143.95 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $119.99 | 2019 | |
| Intercept Pharmaceuticals, INC. | $118.19 | 2023 | Ocaliva |
| Janssen Biotech, INC. | $111.46 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $107.10 | 2022 | |
| Novo Nordisk INC | $94.98 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Erbe USA INC | $92.27 | 2019 | |
| Endogastric Solutions, INC | $80.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.68 | 2019 | |
| Covidien LP | $61.31 | 2019 | |
| Allergan, INC. | $47.66 | 2019 | |
| Ethicon US, LLC | $46.97 | 2019 | |
| Genzyme Corporation | $30.79 | 2023 | |
| Shionogi INC | $28.35 | 2020 | |
| Braintree Laboratories, INC. | $27.50 | 2019 | |
| Pharming Healthcare, INC. | $26.00 | 2023 | |
| Daiichi Sankyo INC. | $23.62 | 2019 | |
| Merck Sharp & Dohme LLC | $17.49 | 2024 | Dificid |
| Shire North American Group INC | $17.19 | 2019 | |
| Evoke Pharma, INC. | $15.69 | 2025 | |
| Pfizer INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feng Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.